画像の出所：https://www.eagletribune.com/region/selux-diagnostics-announces-additional-48-million-in-funding/article_f31eda32-f83e-5107-a6b5-2e20917d5222.html
Selux Diagnostics announced today that they have secured an additional $48 million in funding to further develop their innovative diagnostic technology. The company, based in Lawrence, Massachusetts, specializes in providing rapid and accurate testing solutions for infectious diseases.
This latest round of funding was led by Deerfield Management Company, with participation from existing investors such as M Ventures, Hikma Ventures, and others. Selux Diagnostics plans to use the funds to support the commercial launch of their first product, the BSI1 System, which is designed to rapidly diagnose bloodstream infections and help healthcare providers deliver targeted treatment to patients.
“We are thrilled to receive this additional funding, which will allow us to expand our capabilities and bring our cutting-edge diagnostic technology to market,” said Matthew Borowiecki, CEO of Selux Diagnostics. “We believe that our innovative approach has the potential to revolutionize the field of infectious disease diagnostics and improve patient outcomes.”
Selux Diagnostics was founded in 2017 and has quickly established itself as a leader in the development of advanced diagnostic solutions. The company’s mission is to provide healthcare providers with the tools they need to rapidly and accurately diagnose infectious diseases, ultimately saving lives and reducing healthcare costs.